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Abstract
Background: Deviation from the physiological glucocorticoid dynamics (circadian and underlying ultradian rhythmicity)
is a common characteristic of various neuropsychiatric and endocrine disorders as well as glucocorticoid-based
therapeutics. These states may be accompanied by neuropsychiatric symptomatology, suggesting continuous dynamic
glucocorticoid equilibrium is essential for brain homeostasis.
Methods/design: The study consists of two parts. The preliminary stage of the study aims to validate (technically and
pharmacologically) and optimise three different patterns of systemic cortisol administration in man. These patterns are
based on the combinatory administration of metyrapone, to suppress endogenous cortisol production, and concurrent
hydrocortisone replacement. The second, subsequent, core part of the study is a randomised, double-blinded, placebo-
controlled, crossover study, where participants (healthy male individuals aged 18–60 years) will undergo all three
hydrocortisone replacement schemes. During these infusion regimes, we plan a number of neurobehavioural tests and
imaging of the brain to assess neural processing, emotional reactivity and perception, mood and self-perceived well-
being. The psychological tests include: ecological momentary assessment, P1vital Oxford Emotional Test Battery and
Emotional Potentiated Startle Test, Leeds Sleep Evaluation Questionnaire and the visual working memory task (n-back).
The neuroimaging protocol combines magnetic resonance sequences that capture data related to the functional and
perfusion status of the brain.
Discussion: Results of this clinical trial are designed to evaluate the impact (with possible mechanistic insights) of different
patterns of daily glucocorticoid dynamics on neural processing and reactivity related to emotional perception and mood.
This evidence should contribute to the optimisation of the clinical application of glucocorticoid-based therapeutics.
Trial registration: UK Clinical Research Network, IRAS Ref: 106181, UKCRN-ID-15236 (23 October 2013)
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Emotional processing
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Background
Glucocorticoid dynamics and neurobehavioural equilibrium
The hypothalamic–pituitary–adrenal (HPA) axis is a
complex homeostatic system, consisting of multiple
feedforward and feedback regulatory interactions from
the corticolimbic areas of the brain to the adrenal
cortex [1]. These interactions result in both a circa-
dian and an ultradian rhythm of cortisol secretion [2],
which may be further modified by internal or external
stressors [3].
HPA activity can be classified within two categories: (i)
the regulation of internal homeostatic mechanisms (many
of which have a circadian pattern) and (ii) the coordin-
ation of stress responses. Although there are glucocortic-
oid receptors in almost every tissue of the body, these
hormones’ predominant effects relate to metabolic,
immunological or cognitive functions. The wide spectrum
of glucocorticoid-related biological actions has been
exploited in the field of therapeutics for various disorders,
though long-term use and/or high doses have been
accompanied by numerous side effects [4].
Glucocorticoids modify the physiology of the central
and peripheral nervous system at multiple levels. They
interfere with the molecular processes involved in the
modulation of the neuroinflammatory response, neurode-
generation and neuroregeneration/neurogenesis, neuronal
viability and the cellular metabolic balance of neuronal
and glial populations during developmental stages. More-
over, glucocorticoids regulate the state of activity of most
systems of neurotransmission and synaptic plasticity, es-
pecially under acute stressful conditions or during chronic
post-stress cognitive adaptations. Ultimately, glucocorti-
coids modify the status of emotional reactivity, cognitive
precision and overall behaviour [1].
Glucocorticoid-dependent signalling has been associ-
ated with a number of neurological (stroke, traumatic
brain injury, neurodegenerative disorders) and psychi-
atric disorders (depression, psychosis, post-traumatic
stress disorders, antisocial behaviour, anxiety disorders
and addiction). Similar problems, mainly fatigue, de-
pression or dementia, seem to arise in patients whose
treatment strategy involves high dose and/or long-term
use of glucocorticoid-related therapeutics (even in
cases of substitution therapy), as well as in patients
with endogenous hypersecretion (Cushing’s syndrome)
or deficiency (Addison’s disease, congenital adrenal
hyperplasia) of glucocorticoids [4].
In all of these conditions there is a deviation from
physiological glucocorticoid dynamics. The rationale for
this protocol is therefore to examine whether glucocortic-
oid rhythmicity differentially regulates neural processing
related to mood and emotional perception. These are cog-
nitive aspects controlled via the corticolimbic areas of the
brain and are susceptible to glucocorticoid effects.
Aims of this paper
This article serves the following purposes: (1) the pres-
entation of the study protocol and the underlying scien-
tific evidence that led to its specific design, (2) the
development of a metyrapone and hydrocortisone block
and replace regime that allowed precise pharmacological
manipulation of the underlying glucocorticoid rhythm,
(3) the presentation of the temporal design of our mag-
netic resonance imaging (MRI) protocol and some tech-
nical aspects on approaching neuroimaging analysis,
following the guidelines for reporting functional neuro-
imaging data.
Rationale of the study
The importance of the glucocorticoid circadian rhythm
in maintaining homeostasis has been long recognised.
Nevertheless, there is little evidence available concerning
the clinical impact of the underlying physiological ultra-
dian (pulsatile) rhythm.
Preclinical research work over the last decade has
highlighted the importance of ultradian pulses, which
are synchronised between the blood, subcutaneous tissue
and the brain [5], and lead to rapid and transient activa-
tion of its target receptors, resulting in dynamic gen-
omic, neuroendocrinological and behavioural changes
[6]. Moreover, they differentially affect neuronal plasti-
city and neurotransmission [7].
A number of clinical trials in healthy subjects, using
functional neuroimaging techniques, have added valu-
able insights into the influence that glucocorticoids exert
on cognitive and behavioural functions. Under such ex-
perimental settings, it has been shown that hydrocorti-
sone administration imposes changes in emotional
processing, attention or working memory related to
either alterations in corticolimbic activity or differential
functional connectivity [8–10]. Nevertheless, none of
these clinical trials investigated the relevance of pattern
administration (that is, the relevance of altered
glucocorticoid rhythmicity) to these neurobehavioural
changes. The focus was to contrast the state of high,
stress-related glucocorticoid concentrations to the
normal, non-stress levels, and study either the rapid
(mediated by the activation of the membrane-associated
glucocorticoid receptors) and/or the delayed (mediated
by the activation of the nuclear glucocorticoid receptors)
glucocorticoid effects on cognitive performance and
emotional perception.
Main research questions and hypothesis
Our research team has adopted a novel approach, which
enables us to infuse replacement steroids in either a
physiological circadian rhythm with its underlying ultra-
dian rhythm or as a constant infusion, which abolishes
the ultradian component of the circadian rhythm. This
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will allow us to test our hypothesis that the pattern of
systemic glucocorticoid fluctuations leads to differential
neurobehavioural phenotypes and activation of brain
areas related to mood and emotional processing.
Methods
Overview of the study design
This is a physiological, pilot study on healthy, adult male
volunteers, who will undergo three different strategies of
hydrocortisone replacement after their endogenous gluco-
corticoid production is pharmacologically suppressed in a
safe and reversible manner. The study has two stages: a
preliminary stage (stage 1), where the pharmacological in-
terventions are optimised and biochemically validated
(presented here). The second stage of the study (stage 2)
will be a double-blinded, placebo-controlled, three-way
crossover, neurobehavioural study, in which healthy male
subjects randomly alternate the three different modes of
hydrocortisone replacement. The effect of each condition
is assessed using functional and perfusion imaging of the
brain and a series of psychological measurements asses-
sing emotional reactivity and self-perceived well-being.
For both study parts, the same regulations apply in terms
of inclusion and exclusion criteria, the recruitment
process and biomedical ethics. In the second stage of the
study some additional inclusion and exclusion criteria, as
well as steps in the recruitment process, will be applied
(as discussed below).
Inclusion and exclusion criteria
We shall recruit healthy volunteers, with no medical his-
tory and a normal physical examination assessed during
the screening process by a qualified physician. Volun-
teers must not be casual smokers or consume excessive
amounts of alcohol frequently, and additionally, they
must not consume excessive amounts of caffeinated
drinks (for details refer to Table 1). Since there are age-,
gender- and working routine-specific factors that affect
the mode of HPA axis function [11], this study is limited
to male individuals, aged between 18–60 years old, who
are not shift workers [12]. Furthermore, volunteers are ex-
cluded if they have participated in any other drug trial
within the last two months prior to current study partici-
pation or have used any medication (prescribed, over the
counter or recreational), including topical steroids and
inhalers, within 48 hours of the current study initiation.
Needle phobia was an additional exclusion criterion
during recruitment for stage 1, as 24-hour blood sam-
pling via a cannula is required. For stage 2, volunteers
need to be non-dyslexic, right-handed [13] and fluent in
the English language, to ensure they can respond to vari-
ous verbal stimuli included in the behavioural test and/
or questionnaires. Participants also need to pass MRI
safety screening and must be able to tolerate spending
more than one hour inside the MRI scanner bore. Table 1
gives detailed information about the exclusion criteria.
Recruitment process
For both studies the same recruitment methods have
been used. Study adverts briefly describe the scope of
the investigation and basic inclusion/exclusion criteria.
Posters are being displayed across multiple faculties
within the University of Bristol. Electronic adverts are
being sent to subjects who have expressed interest in
our studies in the past and given permission to be con-
tacted about study opportunities in the future. The study
is also publicly advertised on the University of Bristol
Department of Psychology webpages, and is included in
the monthly newsletter sent to all subscribers of the
Psychology mailing list interested in human research
(subscription is free to all members of the general public).
Table 1 Exclusion criteria of the study
1. Non-healthy individuals
• Previous medical history for any chronic condition in the last three
months, active disease, or abnormal physical examination as verified by
a qualified physician.
2. Casual smoking
• >6 cigarettes per day.
3. Frequent, heavy alcohol consumption
• >21 units/week.
4. Frequent, heavy caffeine consumption
• >4 caffeinated drinks/day.
5. Gender: female
6. Age: < 18 and > 60 years old
7. Shift workers
8. Participation in an investigational drug trial within the past two months
9. Intake of any medication (prescribed, over the counter or recreational)
including topical steroids and inhalers, within 48 hours of the study initiation
• Urine sampling for testing for drugs of abusea
Stage 1 (pharmacological validation) only
10. Needle phobia
Stage 2 (neurobehavioural investigation) only
11. Left-handed or ambidextrous
• Tested with the Edinburgh Handedness Inventory [13]
12. Dyslexia
13. Claustrophobia
14. Contraindication to MRI scan
15. Non English-language users
aUrine sampling for testing for drugs of abuse takes place during the
recruitment process. In addition, during study stage 2 (neurobehavioural
investigation), urine sampling is repeated prior to starting the trial on day 1 of
each of the three study arms, as well as prior to the scanning session on day 5
on each of the three study arms. A seven-drug (multi-panel) dip and read im-
munoassay is being used, offering high accuracy in detecting cocaine, amphet-
amine, methamphetamine, tetrahydrocannabinol (cannabis), opiates,
barbiturates and benzodiazepines (SureScreen Diagnostics®)
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Advertisement for study stage 2 occurs after completion
of stage 1, allowing for optimised treatment schemes (see
below) and temporal design of the neurobehavioural
investigation.
Figures 1 and 2 summarise the study recruitment pro-
cedures for both stages of the study. Standard recruit-
ment procedures are used for both stages of the study.
Interested volunteers may contact the research team via
a secure University email address or telephone number.
If the information provided suggests no reason for initial
exclusion, subjects are sent the participant information
sheet (PIS). The PIS details the aims/scope of the study
in lay language, all clinical and experimental procedures
involved, the ethical framework which governs the study,
the volunteers’ responsibilities and the healthcare and
safety information. After receiving the PIS, participants
have up to six weeks to consider the information and de-
cide if they would like to take part. If interested, partici-
pants are requested to contact the study team by phone
or email. Study investigators can also contact potential
participants after four weeks if no reply has been re-
ceived. All interested participants are initially asked to
take part in a short screening phone call, arranged at a
convenient time. Phone screening allows initial assess-
ment of eligibility and a chance for the investigator to
ensure participants have read and understood the PIS
and what would be involved in the study. Participants
are also encouraged to ask any questions they may have.
If participants are happy to continue and found eligible
at this stage, they are invited to attend a more detailed
screening visit. During that appointment, a detailed,
formal screening process takes place (including the ac-
quisition of a medical history and a physical examin-
ation), all the procedures and the scientific background/
justification and any medical issues related to the study
are discussed and explained in detail. Participants are
again encouraged to raise any concerns or queries, and if
still willing to take part in the study, they are asked to
sign the relevant written consent forms.
Screening for study stage 2 also involves ensuring the
participant is suitable for MRI scanning; this is under-
taken by using specific screening forms. If it is safe to
scan the participant, an additional visit is booked for a
preliminary MRI examination during which a high-
resolution, anatomical MRI scan is acquired. This initial
MRI scan serves two purposes: (1) acquiring the data ne-
cessary for subsequent registration of low-resolution
functional fMRI data to a “standard” MRI template for
neuroanatomical localisation of obtained functional
imaging data, and (2) assessing the ability of the subject
to lie still inside the MRI scanner bore for long periods.
Prior to the scan, participants are also asked to produce
a urine sample to test for drugs of abuse (see Table 1).
Medical issues, quality control, bioethics and trial
monitoring
Local ethical and institutional approval has been ob-
tained. The study was discussed with the Medicines and
Healthcare products Regulatory Authority (MHRA) and
formal approval was deemed unnecessary. The study is
conducted according to the principles of the Research
Governance Framework for Health and Social Care and
Fig. 1 Main steps followed in recruiting and working with volunteers during study stage 1. Interested participants were phone screened, and if
screening was positive, an initial appointment was scheduled to discuss in full detail the parameters of the study and answer any queries. During
that appointment, a full screening process takes place. If participants are still eligible and willing to participate, signed informed consent is obtained. A
date to conduct the five-day interventional study (metyrapone and hydrocortisone administration) is then arranged. The 24-hour study is performed
after midday (around 2:00–3:00 pm) of day 4 until after midday (around 2:00–3:00 pm) of day 5. HABS: human automated blood sampler
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the international conference for harmonisation of good
clinical practice (ICH GCP, declaration of Helsinki). The
study is being performed subject to the Faculty of Sci-
ence Human Research Ethics Committee of the Univer-
sity of Bristol (REC, ethics approval code: 2706132525)
and local Research and Development (R&D) approval of
the University Hospitals Bristol (UHB, National Health
System Foundation Trust) (reference code: ME/2013/
4325). The study is monitored and audited in accord-
ance with the R&D governance procedures of UHB and
the University of Bristol. Case record forms are pro-
duced, and these and all study-related documents will be
made available on request for monitoring and audit by
the Trust, University and REC.
Study-related information and informed consent is
administered by the investigators. Participants receive
information designed to inform them extensively on the
topic of the investigation. This includes information re-
garding the overall study, its goals, methods, health and
safety issues and procedures involved. They also receive
a detailed presentation of the MRI techniques, their lim-
itations and their safety issues. In addition, during the
initial appointment (see above), investigators ensure that
participants’ questions and concerns are addressed and
fully answered. Participants are informed that they have
the right to discontinue their participation at will, at any
time without giving a specific reason. Lastly, participants
are encouraged to contact the research team at any later
point if they feel they require further elaboration on a
study-specific topic. Afterwards, eligible male volunteers
who are still interested in participating in the study are
requested to read and sign a consent form acknowledg-
ing the principles outlined above.
The possible presence of unwanted effects due to the
pharmacological intervention or other medical processes
during the study has been taken into consideration, and
all necessary measures, ensuring participants’ safety, have
been implemented. For instance, side effects of metyra-
pone include nausea, vomiting, drowsiness, abdominal
pain and allergic skin reactions. For this reason, volunteers
are explicitly instructed to accompany pills with food in-
take to avoid/attenuate gastrointestinal discomfort. If side
effects develop, participants are strongly advised to
contact the research team, so the metyrapone dose can be
decreased for 24 hours and increased again, symptoms
allowing.
Potential side effects of (high doses of) hydrocortisone
include problems with disturbed sleeping, abdominal pain
and heartburn. Since all volunteers will be receiving a cor-
tisol blocking agent (metyrapone) in combination with ad-
equate hydrocortisone replacement therapy, there should
be no issues with symptoms related to hypoadrenalism or
cortisol excess. For safety reasons, the risks and symptoms
of a hypoadrenal crisis are explicitly discussed with partici-
pants, as well as what they need to do should they become
unwell at all during the study [14]. An emergency box is
Fig. 2 Main steps followed in recruiting and working with volunteers during study stage 2. Interested participants are phone screened, and if
screening positive, an initial appointment is scheduled to discuss in full detail the parameters of the study and answer any queries. During that
appointment, a detailed screening process would take place. If participants are still eligible and willing to participate, signed informed consent is
obtained. Additionally, as part of the screening process, participants need to give a urine sample to test for drugs of abuse and undergo an initial
anatomical magnetic resonance (MR) scan. If still eligible, the dates for the conduction of the three study arms are arranged. The order of treatment
arm allocation is random and unknown to the volunteers and the study investigators. This is determined by an external authority and takes place prior
to the start of arm 1. Interventions during the three study arms were designed and validated during the previous study stage. Each of the three arms
takes place with a temporal distance from the previous one of at least two weeks (*). EMA: ecological momentary assessment, ETB: emotional test
battery, EPST: emotion potentiated startle test, LD: last study day, LSEQ: Leeds Sleep Evaluation Questionnaire, MRI: magnetic resonance imaging, RAP:
randomisation phase, WP: wash-out period
Kalafatakis et al. Trials  (2016) 17:44 Page 5 of 17
given to all participants for the duration of their study ses-
sions, containing hydrocortisone for intramuscular and
per os administration, as well as other equipment related
to the pump handling and subcutaneous delivery. More-
over, all participants have an emergency card to keep on
their person at all times with details of study drugs
and out-of-hours contact information (24-hour
emergency telephone number).
There is a rare possibility of an anaphylactic reaction
[15] to parenteral hydrocortisone succinate administration
in a subject with no prior history of anaphylaxis. All med-
ical and biomedical procedures related to this study will
occur in the Joint Clinical Research unit at UHB or the
Clinical Research and Imaging Centre of the University of
Bristol (CRICBristol). Both units’ basic resuscitation
equipment has been inspected and agreed to be appropri-
ate by the UHB resuscitation officer, and there is immedi-
ate access to the full resuscitation team if they are needed.
A standard operating procedure and risk assessment for
the procedure includes clear instructions regarding the
presentation and initial management of anaphylaxis.
In case of technical, pump-related and drug delivery-
related issues, such as subcutaneous pump line falling
out/accidental removal, all participants are taught how to
perform a line change (materials provided in the emer-
gency box) and instructed to contact a study researcher
(24-hour emergency telephone number provided) so that
the pump can be checked and a replacement emergency
kit provided. In case of a pump failure/malfunction, sub-
jects are instructed to contact a study researcher. If a
replacement pump cannot be provided within 3 hours, the
subject will be asked to take oral hydrocortisone replace-
ment (provided in the emergency box).
Other minor unwanted effects that may occur during
the study are discomfort, bruising, infection or allergic
reaction at site of insertion of infusion pump/cannula,
vasovagal reaction or bruising due to intravenous cannu-
lation (during the preliminary stage of the study), and a
feeling of claustrophobia during MRI scanning (during
the core part of the study). Adverse events will be re-
corded in accordance with the ICH GCP and the UHB’s
research-related adverse event reporting policy. The
study will be stopped prematurely in the case of
significant adverse events.
Concerning the MRI scans, the subjects are made
aware that these scans are not diagnostic and will be
interpreted solely for the purposes of the study. Never-
theless, study researchers do have a duty of care. As a
consensus between these two principles, this study has
adopted the guidelines provided by Illes et al. [16], which
explain the procedures for dealing with incidental find-
ings in brain imaging research. Based on these guide-
lines, our scanning protocol (see below) contains the
minimum required sequences for research and does not
include extra scans for diagnostic purposes. All scans are
reviewed by a clinically qualified (non-radiologist) mem-
ber of the research team. If any concerns are noted, the
images will be sent for consultation and/or referral to a
radiologist for clinical evaluation. After assessment the
qualified radiologist will report any incidental findings to
the lead researcher and provide guidance on what
should be conveyed to the participant’s primary care
provider (this information is collected at screening).
After reporting, the responsibility for assessing the
importance of the findings and acting on them rests with
the primary care provider.
Volunteers are free to withdraw from the study at any
time. Should a subject withdraw from the study, another
will be recruited in his/her place. It is not anticipated
that withdrawn volunteers will require any follow-up.
With regards to a randomisation and/or blinding code
break during the second stage of the study, a copy of the
codes will be kept in the Bristol Royal Infirmary Univer-
sity Hospital Pharmacy and in the site file. The codes
may only be broken under the following conditions with
the agreement of the chief investigator and REC except
under the case of an emergency: (i) it is deemed clinic-
ally necessary (for example, treatment of an adverse
event is dependent upon knowledge of the drug admin-
istered), (ii) the study must be terminated for safety
reasons, or (iii) a third party requires the information
(for example, a coroner).
Study stage 1: optimising and validating pharmacological
interventions
The aim of the preliminary stage of the study is to define
and validate (technically and pharmacologically) safe
methods to create reliably and reproducibly three different
patterns of plasma cortisol. These patterns were based on
the combinatory administration of metyrapone and hydro-
cortisone. Metyrapone was chosen to suppress endogen-
ous cortisol production for both safety reasons (as it has a
short half-life [17]) and because it does not interfere with
cortisol’s molecular physiology. Metyrapone blocks corti-
sol synthesis by inhibiting steroid 11β-hydroxylase [18].
These three methods for creating different patterns of sys-
temic cortisol dynamics in healthy individuals offered the
basis for the temporal design of study stage 2 (see below).
Five healthy volunteers participate in stage 1. After giv-
ing written consent, they undergo a five-day treatment
scheme, where metyrapone per os (on a full stomach to
minimise gastric side effects) treatment is gradually in-
creased from 0.5 g on day 1 to 2.5 g on day 4 (see Table 2).
Hydrocortisone replacement is achieved in one of three
modes: (i) either orally to mimic the current therapeutic
protocols for glucocorticoid replacement or via a subcuta-
neous pump, delivered (ii) continuously or (iii) in pulses.
The total daily dose of hydrocortisone is: 20 mg (per os),
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19.8 mg (continuous with varying rhythm throughout the
day) [19], 19.9 mg (pulsatile: eight times/day being a close
approximation of the adrenal glucocorticoid natural ultra-
dian pattern of secretion) (see Table 3). For technical rea-
sons, hydrocortisone delivery via the pumps differs very
slightly from the oral 20 mg dose. We have chosen to de-
liver slightly less by subcutaneous infusion to compensate
for the slightly higher blood levels achieved using this
route [20, 21]. Recently, our group has published the tech-
nical data (dose range and frequency of individual pulses
estimation) and the functional validation of the pulsatile
pump [22].
All visits take place in the Joint Clinical Research unit
(UHB). On day 1 participants are fitted with the sub-
cutaneous pump and are given precise instruction on
how to receive their oral medication. On day 3 partici-
pants wearing either of the pumps attend the unit for a
pump syringe and line change. On day 5, the 24-hour
blood sampling study is undertaken, using the human
automated blood sampler (HABS). Blood samples are
collected via an intravenous cannula every one hour for
serum corticotrophin (ACTH) and cortisol concentra-
tion estimation. For those receiving hydrocortisone via
the subcutaneous pulsatile pump, cortisol was being
estimated every 10 minutes, since we anticipated that
cortisol would fluctuate in a more dynamic manner
(approximating its normal, ultradian rhythm). During
the 24-hour sampling procedure, participants give ap-
proximately half a pint of blood (half the amount of
blood taken at blood donation). All blood is replaced
with an equal volume of normal saline.
During the blood sampling period, participants are
served a hot meal at 7:00 pm, breakfast at 07:00 am and
lunch at 12:30 pm. Refreshments are offered between meal
times and recorded. Participants are asked to go to sleep
at 11:00 pm when the lights are switched off. During the
lights-on period, participants are allowed to work, read,
watch films or relax. A member of staff is present in a
room adjacent to the experimental room to monitor them
at all times. At the end of the study (in the early after-
noon), when the intervention is terminated, participants
are instructed to take orally 5 mg of hydrocortisone
during dinner to ensure proper cortisol replacement
for that day. This ensures there has been adequate
time for the metyrapone to have cleared and resump-
tion of endogenous cortisol production. Participants
are called the following day to check that there have
been no adverse events and note any issues they wish
to report.
Cortisol samples were allowed to clot at room
temperature prior to centrifugation and serum was fro-
zen at −80 °C until assayed. Samples for ACTH were
collected in chilled ethylenediaminetetraacetic acid-
containing tubes and kept on ice until centrifugation at
4 °C within 30 minutes. Plasma was stored at −80 °C
until assayed. Analysis is performed by the department
of clinical biochemistry at the UHB using an electroche-
miluminescence immunoassay (Cobas®, Roche). Cross-
reactivity with 11-deoxycortisol was 4.1 %. This im-
munoassay has an intra-assay coefficient of variation
ranging from 1.5 % to 6.1 % on sample concentrations of
0.170 μg/dL to 0.718 μg/dL http://www.accessdata.fda.-
gov/cdrh_docs/reviews/K043175.pdf.
Study stage 2: randomisation and blinding
The second stage of the study is the randomised,
double-blinded, placebo-controlled, three-way crossover
investigation, where participants undergo all three opti-
mised five-day treatment schemes as finalised in the pre-
vious stage. Randomisation schedules were generated
using IBM SPSS® v19 software by staff members not dir-
ectly involved in data collection for this study. Dispens-
ing and processing of all medication/placebo is managed
by Bristol Royal Infirmary University Hospital Pharmacy,
ensuring that study researchers remain blinded to the
conditions. To ensure that the study remains double-
blind, all participants are required to take the same daily
regime of tablets and remain connected to a subcutane-
ous pump (continuous or pulsatile). Each week one of
these treatments will be placebo (either placebo tablets
or 0.9 % saline infusion via the pump). In addition, the
study investigators responsible for care of the pumps
have no input into the psychological testing. There is a
minimum of two weeks between each of the three study
Table 2 Outline of the five-day metyrapone treatment scheme during study stage 1
Medication was received orally (pills of 250 mg of metyrapone). The doses in blue letters have been administered during the 24-hour blood sampling study
aFor the purposes of the optimisation procedure, various doses were tested in different subjects at particular time points during the five-day treatment scheme to
secure effective adrenal gland suppression (see Fig. 4)
bThe last dose of the day was shifted from, initially, dinner time to just before going to sleep to ensure effective adrenal gland suppression during sleep (see Fig. 4).
Participants are strongly advised to take metyrapone with a glass of milk or a snack to avoid any gastric discomfort
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arms. Participants and study researchers are therefore
unaware of the order of the arms of their hydrocortisone
replacement.
On day 1 of each arm, participants are connected to
the pump via a line that is inserted into the subcutane-
ous tissue of the abdomen and are trained to handle the
pump by themselves (detach-reattach). Participants are
given metyrapone and identically encapsulated tablets
containing either hydrocortisone or placebo and the in-
vestigator explains to them the five-day treatment plan
they will follow. The participants receive instructions in
cases of an emergency (hypoadrenal symptoms). Finally,
they also receive their study android phone that moni-
tors their everyday state of mood and reactivity at ran-
dom points within each day (see below). Participants
also give a urine sample to be tested for the presence of
drugs of abuse.
On day 3 participants attend the hospital for a pump
syringe and pump line change, while the investigator
also monitors individuals’ compliance to the treatment
scheme (counting the number of remaining pills) and to
answering the study phone’s questions. Finally, on day 5
participants attend CRICBristol where they undergo
MRI scanning, complete a sleep questionnaire and
undertake a series of behavioural tests (see below). At
the end of the study visit, participants return all study
material (android phone, remaining pills), are discon-
nected from the pump and are instructed to take 5 mg
of hydrocortisone orally during lunch and again during
dinner to ensure proper cortisol replacement for the
remaining day. This ensures there has been adequate
time for the metyrapone to have cleared and resumption
of endogenous cortisol production. They will then re-
ceive a follow-up phone call the following day to check
to see how they are feeling and if they have any issues
they wish to report.
Compliance to the treatment protocol is encouraged
by (1) giving participants at arm day 1 a detailed, written
five-day timetable, with instructions on the timings and
the number of metyrapone and hydrocortisone/placebo
pills they need to take, (2) counting the remaining pills
at arm days 3 and 5 to verify that they are consumed in
the proper quantity, and (3) prompting the participants
at arm day 3 to accurately follow their treatment scheme
and to constantly wear the pump. Furthermore, compli-
ance to the oral treatment protocol is also supported via
three reminder messages (in the morning, at 1:00 pm
and at 7:00 pm) delivered every day through the study
phones carried by each subject.
Assessments during study stage 2
Ecological momentary assessment
This is a subjective test that relies on the repeated, five-
day long collection of real-time data on subjects’ behav-
iour/emotional status in the subjects’ natural environ-
ment. For this purpose, volunteers are asked to
continuously carry a modified android mobile phone, for
the whole duration of each of the three five-day study
periods. This is appropriately programmed to ask some
questions contained in the Identity-Consequence Fatigue
Scale [23] and visual analogue scale [24] concerning the
subjects’ state of reactivity and feeling of well-being.
Time-based sampling is applied; assessments are
solicited based on a time schedule, but at random time
intervals. Additionally the phone reminds the holder to
take his oral study medication. Moreover, the device asks
the subject to complete a morning (available until
around 10:00 am) and an evening report (available at
07:00 pm onwards) each study day. Anonymised data
Table 3 Outline of the three different modes of hydrocortisone
replacement in healthy individuals under metyrapone
administration
Time of day Per os SC continuous SC pulsatile
00:00 0.1 mg/hour 0.5 mg
01:00
02:00 2 mg/hour
03:00 4 mg
04:00
05:00
06:00 4 mg
07:00 After waking up (10 mg)
08:00 1 mg/hour
09:00 4 mg
10:00
11:00
12:00 0.4 mg/hour 2.3 mg
13:00 During lunch (5 mg)
14:00
15:00 2.3 mg
16:00
17:00
18:00 2.3 mg
19:00 During dinner (5 mg)
20:00 0.1 mg/hour
21:00 0.5 mg
22:00
23:00
The last two modes involve the subcutaneous (SC) delivery of hydrocortisone
via a pump; the continuous pump (Animas® Vibe™ Insulin Pump) is programmed
to constantly deliver hydrocortisone but with a changing flow rate throughout
the day. The pulsatile pump (Crono P®, CANE Applied Medical Technology Ltd,
Cambridge, UK) is programmed to deliver a certain amount of hydrocortisone
every three hours with a rhythm of 10 μL/s [22]
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(subjects’ feedback), both quantitative and qualitative,
are stored in the android phone, and are transferred to
University of Bristol computers.
Ecological momentary assessment (EMA) techniques
(versus static retrospective self-reports of behaviour)
take into consideration the dynamic changes in
behaviour over time and across situations and under a
real-world setting. Moreover, they avoid relying on indi-
viduals’ autobiographical memory (which is the case in
retrospective self-reports), which is prone to random
error but also fraught with systematic bias [25]. Evidence
from other clinical studies, such as smoking cessation,
indicates that ambulatory monitoring of subjective states
provides greater temporal resolution than can be
achieved by laboratory assessments [26, 27]. This setting
provides rich and detailed information on both the back-
ground level of mood and well-being (tonic levels), as
well as the frequency and magnitude of acute fluctua-
tions (phasic variation), and identifies specific periods
when these occur (for example, early morning). EMA
data offer the opportunity to evaluate hypotheses regard-
ing the dynamic interactions among processes over
time—in our case, how different systemic cortisol
dynamics could affect reactivity, mood and well-being
perception [28, 29].
Leeds Sleep Evaluation Questionnaire
During day 5 of each study arm participants are asked to
complete the Leeds Sleep Evaluation Questionnaire
(LSEQ). This scale comprises ten self-rating 100-mm-
line visual analogue questions evaluating four main com-
ponents: sleep initiation, sleep quality, ease of waking
and behaviour following waking. Anonymised data is
transferred to the University of Bristol computers. Appli-
cation of the LSEQ offers consistent and meaningful
findings concerning subjectively perceived changes in
sleep during psychopharmacological investigations, of-
fering good retest reliability, cross-cultural validity and
stability across a range of clinical settings [30–32].
Moreover, it has recently been used to correlate basal
diurnal salivary cortisol profiles with sleep quality [33].
P1vital Oxford behavioural assessments
Participants undertake a series of emotion-related
experimental paradigms, primarily designed to measure
biases in emotional processing that are thought to be
core components of depression [34]. The P1vital® Oxford
Emotional Test Battery (ETB) consists (in our study de-
sign) of four paradigms consecutively run during one
session which takes place during the fifth day per study
arm. The paradigms follow the same order as presented
below. The Facial Expression Recognition Task (FERT)
assesses the interpretation of facial expressions. Faces of
six different basic emotions (happiness, fear, anger,
disgust, sadness, surprise) are displayed on the screen
and subjects are required to indicate the expression of
the face via a button-press. Different intensity levels of
each emotion are presented, which increases the ambi-
guity of the facial expression and the sensitivity of the
task. The Emotional Categorisation Task (ECAT) as-
sesses speed to respond to positive and negative self-
referent personality descriptors. Sixty personality charac-
teristics selected to be disagreeable or agreeable are pre-
sented. The subjects are asked whether they would like
or dislike to be referred to as each characteristic. The
Faces Dot Probe Task (FDOT) assesses attention to posi-
tive versus negative stimuli using a reaction time meas-
ure. Two faces are presented vertically on the computer
screen and replaced by a pair of dots, to which the sub-
ject has to respond by indicating whether the dots are
vertically or horizontally aligned. During some trials, one
of the two faces presented has an emotional expression
(fearful or happy). The reaction time to respond to the
dots presented in the same or different location to the
face stimuli can be used as a measure of attention to the
emotional faces. The stimuli are presented either masked
(briefly and replaced by a scrambled face stimulus) or
unmasked (subject to conscious awareness). Lastly, the
Emotional Recall Task (EREC) is a surprise free recall
task to assess the incidental encoding of emotional stim-
uli. Subjects are asked to recall as many of the words
previously presented in the ECAT task as they can. The
relative recall of positive versus negative words gives a
measure of emotional biases in memory. Contrary to all
previous tasks, the latter one is not computerised (sub-
jects write the recalled words on a piece of paper).
Another behavioural test that participants undergo dur-
ing the fifth day of each study arm is the P1vital® Oxford
Emotion Potentiated Startle Test (EPST). EPST is de-
signed to provide an objective measure of response to dif-
ferent emotional stimuli [35]. Subjects are exposed to
three consecutive blocks of visual stimuli (= photographs
from the International Affective Picture System database
with positive, negative or neutral content), while being
synchronously exposed to temporally random acoustic
stimuli (startle-eliciting pulses through white noise). Star-
tle responses are recorded using electromyography of the
orbicularis oculi muscle. Electromyographic data are
stored anonymously in the University of Bristol electronic
databases.
FERT, ECAT, FDOT, EREC and EPST have been used
in previous behavioural and fMRI studies and have been
established as models of emotional and cognitive pro-
cessing sensitive to the effects of neuropsychopharmaco-
logical interventions [36]. Moreover, the test-retest
reliability of these tasks is good for the purposes of this
crossover study, with the exception of FERT where per-
formance of healthy subjects was found improved one
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week after a baseline test, though the relative effect of
specific emotions was unaltered [37]. To overcome this
issue and despite the fact that our test-retest period will
be longer than a week, we have introduced different fa-
cial stimuli per testing session.
N-back
During the fifth day of each study arm, participants are
asked to undertake a cognitive test measuring aspects of
working memory. In this task, a series of letters will ap-
pear on the screen one at a time. The participant needs to
make a response as to whether the letter that he sees each
time on the screen matches a letter presented previously
(= reference letter). This continuously changing reference
letter depends on instructions that appear at the beginning
of each of the many letter sequences. If the appearing let-
ter matches the reference letter, he should press a button
labelled as “same”, and in all other cases a button labelled
as “different”. In the one-back task, the reference letter is
every previous letter, in the two-back test the reference
letter is every second previous letter and in the three-back
test every third previous letter. All data are anonymously
stored in the University of Bristol computers.
The n-back task captures the active part of working
memory. When n equals 2 or more, it is not enough to
simply keep a representation of recently presented items
in mind; the working memory buffer needs also to be up-
dated continuously to keep track of what the current
stimulus must be compared to. To accomplish this task,
the subject needs to both maintain and manipulate infor-
mation in working memory. This task has been shown to
activate frontal and parietal cortical regions, among them
the dorsolateral prefrontal cortex [38]. Moreover, the n-
back has a good test-retest reliability in terms of the
neural processing recruited for this cognitive task [39],
while behaviourally, daily practice for a duration of weeks
is required to gain any significant benefits in performance
[40] independent of any experimental conditions.
Functional and perfusion imaging
During the fifth day of each study arm, participants
undergo a specific brain MR scanning protocol. The
protocol consists of two block-designed task-based fMRI
paradigms (see Fig. 3), a resting state fMRI, a pseudo-
continuous arterial spin labelling-based perfusion im-
aging scan (using six post-labelling delays; 0.25 s, 0.50 s,
0.75 s, 1.00 s, 1.25 s, 1.5 s), as well as a number of sup-
portive MRI sequences. The temporal design of the MR
scanning protocol is based on the results of study stage
1 (see below and Table 4). Table 5 presents some tech-
nical details about the MRI experiment, following the
guidelines for reporting an fMRI study, as presented in
Poldrack et al. [41]. To confront with the low test-retest
reliability of the facial expression processing task [39], as
with FERT, we are introducing different facial stimuli
per testing session. Note that the mean test-retest period
is anticipated to be larger than 14.6 days, which is the
one tested in Plichta et al. [39].
The determination of the brain regions of interest
(ROIs) in our study is based on the following criteria: (1)
areas which are glucocorticoid-sensitive (that is, express
glucocorticoid and mineralocorticoid receptors) accord-
ing to the most up-to-date knowledge [42–46], while at
the same time (2) are implicated in (face) emotional pro-
cessing and mood regulation [47–51]. Based on the
above criteria, eight ROIs have been pre-selected: amyg-
dala, prefrontal cortex (with particular focus on orbito-
frontal cortex), insular cortex, dorsal striatum (part of
basal ganglia), nucleus accumbens (part of ventral
striatum), hippocampal formation, and anterior and
posterior cingulate cortex.
Power analysis: how many subjects in study stage 2?
With a sample size of 15 participants on whom
complete data are available, we will have 80 % power at
an alpha level of 5 % to detect an effect size equivalent
to f = 0.35. This is our current best estimate of the likely
effect size across the three conditions of our study,
based on work in other settings using pharmacological
challenge (for example, antidepressants) to probe these
psychological mechanisms.
Data analysis for study stage 2
For the EMA data, the area under the curve will be calcu-
lated for measures of tiredness and mood. These will be
used as the primary outcome variable. Secondary analyses
will be conducted on other derived variables, such as the
degree of variability in tiredness and mood over time (that
is, amplitude). In ETB and n-back tasks, interpretation of
the neurobehavioural phenotypes will result from co-
evaluating the percentage of correct and false responses,
the mean latency of correct responses (in milliseconds)
and percentage of non-responses among the different
study groups [35, 52]. The recorded task measures of
accuracy, reaction times, and — where relevant — signal
magnitude will be grouped according to relevant stimulus
properties such as valence (positive/neutral/negative) and
analysed for effects of pharmacological treatment using
analyses of variance (ANOVA). In EPST, the presence and
magnitude of eye blinking in response to white noise will
also be grouped according to relevant stimulus valence
(positive/neutral/negative) and compared across the three
different groups using ANOVA. This will also be done in
LSEQ.
At the individual level, functional imaging data will be
pre-processed to remove the influence of external factors
like magnetic field inhomogeneities and motion artefacts,
extract the brain from the skull and other soft tissues, co-
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register different imaging modalities (low-resolution
functional images with the corresponding high-resolution
anatomical image) with a standard reference template
(MNI152). Prior to model estimation, the time series
blood oxygen level-dependent (BOLD) data will be
temporally filtered (high pass) and spatially smoothed in
an effort to improve the signal-to-noise ratio. A general
linear model will be applied to the task-based fMRI data
to estimate BOLD signal change associated with each
paradigm. Subsequent group effects will be assessed via
mixed effects inference with a Bayesian two-level model
with fast approximation to posterior probability of activa-
tion using Functional Magnetic Resonance Imaging of the
Brain (FMRIB) Software Library (FSL) software [53] in
combination with statistical parametric mapping (SPM)
software [54]. Other techniques will be recruited to
explore functional connectivity of the brain.
Discussion
This project aims to investigate the impact of dynamic
changes in glucocorticoid rhythmicity on neural process-
ing of emotional perception as well as cognitive and be-
havioural phenotypes in healthy male individuals, utilising
functional imaging of the brain and a series of cognitive
and psychological tests. To test this we are using a
double-blind, three-way crossover randomised design.
This will allow us to perform within-subject analysis, com-
paring three methods of hydrocortisone delivery: oral,
(subcutaneous) continuous and (subcutaneous) pulsatile.
Determination of the inclusion and exclusion criteria was
based on a number of known neuroendocrinological and
neurophysiological factors that could alter HPA axis func-
tion and bias results. Nicotine, alcohol and caffeine [55–57]
are known to elevate cortisol and are carefully controlled
for at screening and then during the study. Concurrent use
of other prescribed drugs (especially steroid-based) or rec-
reational substances may also influence HPA axis function
[58], and may confound functional neuroimaging data [59].
Only male individuals were recruited for this study, as
there is a sexually dimorphic difference in the behaviour
in response to cortisol [60, 61] and functional variations
in the neuroanatomical distribution of glucocorticoid-
mediated cognitive and emotional processing [62, 63]. In
relation to our study, a recent meta-analysis [64] has
indicated a sex-dependent difference in the effect size of
the BOLD signal response of amygdala after exposure to
emotional faces, which is one of the main fMRI para-
digms we use. In addition, response of female individuals
to hydrocortisone is modulated by oral contraceptive use
and varies over the menstrual cycle [65], with the latter
Fig. 3 Tasks of controlled block design used during the functional neuroimaging protocol. a During the implicit facial expression processing task,
individuals are exposed to alternating visual stimuli (pictures) consisting of 30-second blocks of human faces with a particular facial expression
(fear -F- or happiness -H- or sadness -S). Each block corresponds to one kind of facial expression, where 10 different human faces, male or female,
with the same facial expression are presented for 0.1 second with a 2.9-second inter-stimulus interval. Blocks are divided from each other by resting
state periods (lasting 30 seconds). Each kind of block (F, H, S) is repeated four times. The paradigm starts and finishes with a resting state period.
Participants are given a button box and explicitly instructed to press a corresponding button depending on whether the face they see each time is
male or female (gender discrimination). Both accuracy and response time are recorded. b During the flashing checkerboard task, individuals are visually
exposed to a flashing checkerboard (a checkerboard whose cells alternate between white and black colours with a frequency of 7.5 Hz) for 16 seconds
followed by a resting period of 15 seconds before the next flashing checkerboard visual stimulation initiates. The resting period-flashing checkerboard
alternation is repeated 10 times. Subjects are instructed to have their eyes open and look at the screen all the time
Table 4 Temporal design of study stage 2 and the concurrent
relative glucocorticoid dynamics per study group
Cortisol dynamics
Ultr. Circ. PO
MRI scanning protocol 08:45–10:00 am
• Localizer 08:45–09:05 am D S D
• TOF_3D_Neck 08:45–09:05 am D S D
• EPI_2D_Resting State 08:50–09:10 am S S D
• EPI_2D_Zshim_calibration 09:00–09:15 am A S D
• EPI_2D_Zshim_IFEPT 09:05–09:30 am A S D-S
• EPI_2D_pCASL 09:20–09:45 am A S D-S
• GRE_field mapping 09:35–09:50 am A S D-S
• EPI_2D_Zshim_FCT 09:40–09:55 am S S D-S
LSEQ 10:00–10:20 am D S S
Oxford P1vital ETB 10:15–10:50 am D S S
N-back 11:10–11:40 am D-S S S
Oxford P1vital EPST 12:05–12:50 pm A S-D S-D
Non-task scans will include perfusion imaging (pCASL), supportive imaging to
reduce geometric distortions (Z-shimming calibration and field mapping) to
allow for increased accuracy of analysis, and resting state imaging to assess
functional connectivity. The EPI_2D_Zshim_calibration sequence is specifically
designed to reduced signal dropout from the orbitofrontal cortices. 2/3D:
two-/three-dimensional, A ascending cortisol levels, pCASL pseudo-continuous
arterial spin labelling, Circ. circadian (without the ultradian component),
D descending cortisol levels, EPI echo planar imaging, ETB emotional test
battery, EPST emotion potentiated startle task, FCT flashing checkerboard
task, GRE gradient recalled echo, IFEPT implicit face expression processing
task, LSEQ Leeds Sleep Evaluation Questionnaire, PO per os, S steady (no
significant changes in) cortisol levels, TOF time-of-flight, Ultr. ultradian and
circadian rhythm, Zshim shimming along the Z axis
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being difficult to control for, given the crossover nature
of the study.
In this study the control of handedness is also import-
ant, as there is evidence for a positive relationship be-
tween degree of handedness and degree of cerebral
lateralisation for processing emotional faces in men [66].
Dyslexia has been related to impaired processing of
rapid stimulus sequences [67] similar to the ones used in
our study, and was therefore controlled for.
The issue of cultural differences and the extent of
universality in emotional perception is very complex. In
general, happiness, anger and (dynamic) non-verbal
channels of communication are parameters that show
less cross-cultural variability (that is, are characterised
by a lesser within-cultural-group advantage) [68]. During
the design of study stage 2, we avoided setting cultural/
racial criteria in our recruitment strategy for ethical
reasons; rather we chose to primarily rely on investiga-
tional tools of emotional perception that show the least
possible cross-cultural variability.
General intelligence was not controlled for in this
study, as there is no convincing evidence suggesting that
the degree of general intelligence is linked to particular
patterns of brain morphology [69] or frontal and corti-
colimbic activation patterns under emotional stimulation
[70], which are our regions of interest. Other individual
differences (intrinsic environmental and genetic factors)
could not be assessed and consequently could not be
controlled.
All three methods for creating different daily patterns
of circulating glucocorticoids are based on the combined
treatment of metyrapone and hydrocortisone. This offers
a direct relevance for the treatment of actual patients
with hypoadrenalism. Thus, this study could potentially
also provide pilot data on whether replication of the ul-
tradian pattern in glucocorticoid-based therapeutics
could improve treatment efficiency and attenuate side
effects. Even in the case of adrenal insufficiency, re-
placement therapy under the established therapeutic pro-
tocols is accompanied by a higher mortality rate,
increased morbidity from poor quality of life (mental and
physical fatigue, cardiovascular, malignant and infectious
diseases), increased psychosocial needs and morning fa-
tigue compared to normal individuals [71]. The presence
of neuropsychiatric symptomatology, and all other iatro-
genic problems, in these patients suggests that temporal
aspects of glucocorticoid therapy may be helpful in
achieving their homeostatic effects rather than their dele-
terious side effects.
The optimisation process for our metyrapone blockage
and hydrocortisone replacement therapy is based on two
criteria: (1) the preservation of systemic cortisol levels
within a physiological range during hydrocortisone re-
placement, and (2) the suppression of the endogenous
adrenal activity during the 24-hour studies. Endogenous
adrenal activity can be biochemically discriminated from
exogenous hydrocortisone administration in these par-
ticipants due to the prolonged interval (10–12 hours)
between the last per os hydrocortisone dose of day 4
(around 07:00 pm) and the first hydrocortisone dose of
day 5 (around 07:00 am). Based on the above criteria, we
have derived the ideal metyrapone treatment dose for
Table 5 Technical image properties of the three functional MR sequences used for data acquisition
MRI system
Siemens Magnetom Skyra syngo MR D13C (3 tesla)
MRI acquisition details
IFEPT FCT RS
Volumes 250 105 180
Pulse sequence type EPI EPI EPI
FOV 192 mm 192 mm 192 mm
Matrix size 64x64 mm 64x64 mm 64x64 mm
Slice thickness 3 mm 3 mm 3.5 mm
Acquisition orientation T > C-30.0 > S2.3 T > C-30.0 > S2.3 T > C-30.0 > S2.3
Whole brain? Yes Yes Yes
Bandwidth 2298 Hz/Px 2298 Hz/Px 2170 Hz/Px
Order of acquisition Interleaved Interleaved Interleaved
TE 30 ms 30 ms 28 ms
TR 3,000 ms 3,000 ms 2,040 ms
Flip angle 87° 87° 89°
C coronal, EPI echo planar imaging, IFEPT implicit face expression processing task, FCT flashing checkerboard task, FOV field of view, RS resting state imaging, S
sagittal, T transverse (axial), TE echo time, TR repetition time
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study days 4 and 5 as: 0.75 g during breakfast (day 4),
0.75 g during lunch (day 4) and 1 g before going to sleep
at night (day 4) and 0.75 g during breakfast (day 5). This
treatment strategy effectively suppresses endogenous ad-
renal activity in a reversible manner and results in
plasma cortisol profiles that reliably reflect the pattern
of exogenous hydrocortisone administration. This is also
confirmed with the subcutaneous hydrocortisone re-
placement [19, 22] strategies (see Figs. 5 and 6) in
two other healthy male volunteers. None of these five
participants reported any side effects (expected or
unexpected).
During the neurobehavioural investigation, 15 partici-
pants will undergo all three methods of hydrocortisone
delivery for five days as optimised during the previous
study stage. EMA via the android phone will gather daily
data about self-perceived mood and emotional reactivity
of each subject, during these five-day periods. On the
final day of each study arm (day 5), participants will
undergo a number of neurobehavioural tests (see
Table 4). Based on the biochemical results of the prelim-
inary stage of the study (Figs. 4, 5 and 6), the MR scan-
ning will take place between 8:45–10:00 am. During this
period of time glucocorticoid dynamics among the three
study groups show distinctly different motifs (see
Table 4). The EPST will take place after 12:00 pm to
capture the effect of the pulsatile mode of replacement
which results in a rising phase in the subjects’ plasma
cortisol levels in contrast to the other two study groups.
Overall, as seen in Table 4, the exact time periods during
which participants are scanned and tested during arm
day 5 of study stage 2 correspond to specific phases of
circulating cortisol dynamics per treatment strategy.
A last point worth mentioning concerns the study
groups selected for this study. Theoretically, two extra
groups could have been added to the investigational
framework: one group of minimal glucocorticoid effect
(for instance, metyrapone-only treatment) and a “control
group” with no treatment intervention. Both of these
groups would have been problematic from a scientific
point of view. A metyrapone-only treated group would
render otherwise healthy (but for the purposes of the study
hypoadrenal) subjects prone to life-threatening hypoadrenal
crisis. In addition, metyrapone would not only deplete the
presence of glucocorticoids in the brain but would also en-
hance precursors such as 11-deoxycortisol and 11-
deoxycorticosterone, which have been recently shown to
provoke neuromodulatory effects [72]. On the other hand,
little would be known about the temporal pattern of circu-
lating cortisol in the control group, as this would be differ-
ent in each participant. Thus, the psychological tests and
fMRI scanning would be performed at random times
Fig. 4 Systemic 24-hour cortisol profiles of three individuals participating in study stage 1. All participants were under the combined treatment of
metyrapone and hydrocortisone per os. The pattern of oral hydrocortisone administration is presented in Table 3, and was identical in all three
participants. Metyrapone treatment differed between the three individuals as indicated in the corresponding small tables within the figure; for
each small table, each column represents a study day and each row represents the time point within the day in chronological order (during
breakfast, lunch and in the evening) to receive metyrapone. The numbers within the small tables’ cells represent the number of metyrapone pills
administered (1 pill = 250 mg metyrapone). Circulating cortisol levels in participant A exceeded normal values at all periods of his 24-hour study,
while during his sleep period cortisol pulses were present (red part of the curve) which could not be explained by substitution therapy. Thus,
adrenal gland suppression was ineffective. For participant B, the evening dose at every study day was transferred from dinner time to just prior to
going to sleep for the night, and a number of doses during study days 3, 4 and 5 were increased from 2 to 3 pills, as indicated in red colour in
corresponding small table. Circulating cortisol levels in participant B remained under normal values at all periods of his 24-hour study except for
the morning peak and some signs of endogenous adrenal activity just prior to awaking (red part of the curve). For participant C, the evening dose
of study day 4 was further increased from 3 to 4 pills as indicated in red colour in corresponding small table. Based on the biochemical results of
participant C, this last metyrapone treatment scheme was adapted as the ideal one to effectively suppress adrenal gland for the exogenous
hydrocortisone administration to reliably define the exogenously derived pattern of circulating cortisol dynamics
Kalafatakis et al. Trials  (2016) 17:44 Page 13 of 17
during the subjects’ ultradian cycles, preventing the ability
to place them into a biological context and interpret them
in relation to physiology.
Any data extracted from this study will be subject to
some limitations. Compliance of participants to the vari-
ous treatment strategies, though monitored in multiple
ways, will depend on their personality and motivation.
Moreover, glucocorticoid effects on the brain present
gender- and age-related differences [11]; thus, the results
will not be necessarily generalizable. Due to technical
reasons, we are not able to monitor the dynamic cortisol
fluctuations during the neurobehavioural outcome
Fig. 5 Optimised metyrapone treatment and subcutaneously continuous hydrocortisone replacement. Plasma 24-hour cortisol and corticotrophin
(ACTH) profiles of one individual participating in study stage 1. The subject received the optimal metyrapone (Fig. 4, participant C) along with
hydrocortisone substitution therapy, subcutaneously (SC), in a continuous manner via Animas® Vibe™ Insulin Pump. The pattern of continuous SC
hydrocortisone administration is presented in Table 3; between 08:00 pm–02:00 am the flow rate of hydrocortisone substitution is 0.1 mg/h, followed
by an increase to 2 mg/h between 02:00–08:00 am, to drop to 1 mg/h between 08:00 am–12:00 pm, followed by a further decline to 0.4 mg/h
between 12:00–08:00 pm. (Total daily dose adds up to 19.8 mg/day.) The black arrows indicate the time points of shifting from one flow rate to the
next. Due to technical problems, blood samples of the first 5 hours of the study could not be analysed. This mode of hydrocortisone replacement tries
to mimic the normal circadian profile (daily cortisol levels rise in the early morning hours reaching their peak around 08:00 am, near 500 nmol/L before
starting to fall throughout the rest of the day to reach their trough around 02:00 am of the next day, near 50 nmol/L) but without the physiologically
underlying ultradian rhythm. ACTH fluctuations within normal values confirm the physiological state of the hypothalamic-pituitary-adrenal axis.
Fig. 6 Optimised metyrapone treatment and subcutaneously pulsatile hydrocortisone replacement. Plasma 24-hour cortisol and corticotrophin
(ACTH) profiles of one individual participating in study stage 1. The subject received the optimal metyrapone (Fig. 4, participant C) along with
hydrocortisone substitution therapy, subcutaneously (SC), in a pulsatile manner via Crono P® pump (CANE Applied Medical Technology Ltd,
Cambridge, UK). The pattern of pulsatile SC hydrocortisone administration is presented in Table 3; pulses are also indicated as black arrows in
the figure. Corresponding dose of hydrocortisone is indicated above each arrow (adding up to 19.9 mg/day). This mode of hydrocortisone
replacement tries to approximate the physiological (normal circadian and underlying ultradian) profile of endogenous cortisol secretion. ACTH
fluctuations within normal values confirm the physiological state of the hypothalamic-pituitary-adrenal axis
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measures as is achieved during the preliminary stage.
Thus, during study stage 2, cortisol dynamics will be
based on the 24-hour profiles determined during study
stage 1. Concerning functional neuroimaging data inter-
pretation, the limitations in spatially correlating activa-
tion areas with underlying neuroanatomy, as well as the
synaptic rather than neuronal activity-related origin of
the BOLD signal [73], must be taken into consideration.
In summary, this study aims to shed light on the impact
of different patterns of daily glucocorticoid dynamics on
neural processing, emotional reactivity and perception,
mood and self-perceived well-being. For this purpose, the
study adopts an interventional approach based on per os
metyrapone treatment, suppressing in a safe manner en-
dogenous cortisol production, coupled with three alterna-
tive patterns of exogenous hydrocortisone replacement.
Outcome measures include a range of neurobehavioural
tests as well as functional brain imaging. This study
should provide novel evidence for the importance of corti-
sol rhythmicity in dynamically regulating circuits of the
brain responsible for emotional processing, and its poten-
tial in the clinical application of glucocorticoid-based
therapeutics.
Trial status
At the time of the manuscript submission (31 August
2015) the trial was ongoing (study status: recruiting).
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